This study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and …
Phase: PHASE2 • Sponsor: Atish Choudhury, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC